Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoladex and Casodex in advanced prostate cancer
NCT03971110Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Primary completion
- Nov 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of goserelin, bicalutamide in prostate cancer (PCa), sponsored by AstraZeneca. Started Jan 2021; status: terminated.
02
Drugs
goserelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03971110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971110.